Key Highlights
- Novavax surged to $12.56 and Emergent BioSolutions jumped to $7.57 on Monday, Oct. 5, though reports differed on the size of Emergent's gain.
- Reports said a 28-year-old worker at Russia's Irkutsk Anti-Plague Research Institute died of a suspected case of pneumonic plague, a case that has not been confirmed.
- Market commentary described Novavax's move as a squeeze-style rally and noted that plague is a bacterial disease while Novavax makes protein-based vaccines against viruses.
- Irkutsk Governor Igor Kobzev said no new cases of staff seeking medical attention had been identified in recent days.
Two US-listed vaccine and biodefense stocks jumped sharply on Monday, Oct. 5, after reports of a suspected plague case in Russia. Novavax (NASDAQ:NVAX) surged to $12.56, while Emergent BioSolutions (NYSE:EBS) jumped to $7.57, according to market data, though reports differed on the size of Emergent's gain.
According to market data, a 28-year-old worker at Russia's Irkutsk Anti-Plague Research Institute died of a suspected case of pneumonic plague. The case has not been confirmed. Reports described it as "pneumonia of unknown etiology," and at least 197 people were reported to be under observation or quarantine.
What officials said
Irkutsk Governor Igor Kobzev said "over the past few days, no new cases of staff from the Anti-Plague Institute seeking medical attention have been identified."
In the United States, Secretary of State Marco Rubio was monitoring the situation, according to reports. The State Department said it was "coordination with the Centers for Disease Control and Prevention and interagency partners, pressing Moscow to share accurate and timely information."
Why the stocks moved
Emergent BioSolutions makes medical countermeasures for public health threats, including products aimed at biological agents, and market commentary tied its rally to a biodefense bid on the Russian reports. Stocks in this niche often react quickly to headlines about infectious disease outbreaks, even before the facts are established.
The Novavax move was more complex. Market commentary described it as a squeeze-style rally, noting that a large share of the company's float is sold short. A short squeeze happens when a heavily shorted stock rises quickly and traders who bet against it buy shares to close their positions, which can push the price higher still. Market commentary also noted a disconnect: plague is a bacterial disease, while Novavax makes protein-based vaccines against viruses.
Vaccine stocks had another tailwind on Monday. Vaxcyte (NASDAQ:PCVX) soared after positive Phase 3 data for its pneumococcal vaccine, and market commentary said that Novavax outran Moderna (NASDAQ:MRNA) as the Vaxcyte news spread. Moderna climbed ahead of its Oct. 9 entry into the Nasdaq-100.
Health care's split session
The biodefense spike stood apart from the wider health care sector, which was the weakest group at midday. Merck (NYSE:MRK) fell to become the worst stock in the Dow, and Bristol-Myers Squibb (NYSE:BMY) slid after a Leerink Partners downgrade. Life-science tools makers bucked the trend, led by Charles River Laboratories (NYSE:CRL).
The broader market rose. The Nasdaq Composite climbed 286.45 points to a record 27,477.31, the S&P 500 added 51.23 points to 7,773.95, just shy of its record, and the Dow gained 90.94 points to 51,267.90. The Russell 2000, home to both Novavax and Emergent, rose 14.24 points to 2,847.14.
Friday's weak jobs report, showing payrolls up just 29,000, cut bets on an October Fed rate hike. The 10-year Treasury yield still climbed to its highest level since 2002.
Confirmation or rebuttal of the Irkutsk case will decide the rally
The key question is whether health authorities confirm or rule out plague in the Irkutsk case, and whether any new cases emerge. Moves driven by unconfirmed reports can reverse quickly once more information is available, and officials in Russia and the United States have so far offered limited detail.
For Novavax and Emergent, the companies' next quarterly reports will give a clearer picture of their underlying businesses. For the wider market, the Fed releases minutes from its September meeting on Wednesday, Oct. 7, at 2 p.m. ET, and bank earnings start on Oct. 13.






Please wait processing your request...